文献速递白血病

RNA测序:揭示儿童B-其他型急性淋巴细胞白血病转录图谱的可靠工具

RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2025-03-30

该研究将RNA测序结果与临床常规诊断数据整合,用于60例B-其他型急性淋巴细胞白血病(B-other ALL)患儿的真实世界场景分析,共鉴定出49个重排(含32种不同融合基因,见于41例患者,占68%),并将72%的患者(43/60)重新归类为11种新描述的遗传学亚型,其中DUX4重排和PAX5alt最为常见。

要点

  • 在60例B-其他型儿童ALL中,RNA测序共鉴定出49个重排,包括41例患者(68%)中的32种不同融合基因。
  • RNA测序与常规诊断数据整合后,可将72%的患者(43/60)归类为11种不同遗传学亚型,以DUX4重排和PAX5alt最常见。
  • 研究报道了6种新重排:IGK::PAX5、PAX5::IL1RAPL1、ETV6::KRT78、IGH::HIC1、IGH::MIR100HG和NKAIN4::PNPLA7。

核心结论

  • RNA测序是识别新出现的遗传学亚型的可靠工具,有助于改善儿童B细胞前体急性淋巴细胞白血病(BCP-ALL)患者的遗传风险分层,推动更个性化的医疗。

研究设计与样本

  • 研究在真实世界场景中将RNA测序结果与临床常规诊断数据整合,分析60例B-其他型ALL患者队列,以识别新生物标志物并重新归类为新描述的遗传学亚型。

主要发现

  • 共鉴定出49个重排,包括41例B-其他型患者(68%)中的32种不同融合基因。
  • 报道了6种新重排:IGK::PAX5、PAX5::IL1RAPL1、ETV6::KRT78、IGH::HIC1、IGH::MIR100HG和NKAIN4::PNPLA7。
  • RNA测序结果与标准诊疗数据整合后,将72%的患者(43/60)归类为11种不同亚型,其中DUX4重排和PAX5alt亚型最为常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) comprises multiple subtypes characterized by different genetic alterations. With the use of current standard-of-care tests used in clinical practice, 20%-30% of the cases may not be classified into the main genetic subtypes and additional approaches are needed. These patients are grouped in the heterogeneous category B-other ALL. Transcriptome sequencing (RNA-seq) has allowed the identification of novel fusion genes and gene expression profiles that define new molecular subtypes. We present RNA-seq results integrated, in a real-world scenario, with clinical routine diagnostic data to identify new biomarkers and reclassify a cohort of 60 B-other ALL patients in the newly described genetic subtypes. Overall, 49 rearrangements were identified, including 32 different fusion genes in 41 B-other patients (68%). Moreover, we reported six novel rearrangements (IGK::PAX5, PAX5::IL1RAPL1, ETV6::KRT78, IGH::HIC1, IGH::MIR100HG and NKAIN4::PNPLA7). The integration of RNA-seq results with standard-of-care data allowed us to classify 72% of the patients (43/60) in 11 different subtypes, being DUX4 rearranged and PAX5alt the most represented subtypes. In summary, RNA-seq is a reliable tool for the identification of new emerging genetic subtypes contributing to a better genetic risk stratification of BCP-ALL paediatric patients on the path towards a more personalized medicine.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Vicente-Garcés C, Fernández G, Esperanza-Cebollada E, et al. RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia. Br J Haematol. 2025. PMID: 40159352. doi:10.1111/bjh.20056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。